CliffBio
small molecule

JUXTAPID

LOMITAPIDE MESYLATE

Loss of exclusivityFebruary 2029FDA regulatory exclusivity expiry
CompanyCHIESI FARMACEUTICI SPA

Drug detail

Brand nameJUXTAPID
Active ingredientLOMITAPIDE MESYLATE
StrengthEQ 40MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2015
Marketing statusDISCN

Listed patents

PatentExpiresType
7932268August 2027use U-1316

Regulatory exclusivity

CodeExpires
NPPFebruary 2029

More from CHIESI FARMACEUTICI SPA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

JUXTAPID patent cliff — loss of exclusivity February 2029 | CliffBio